Proton Pump Inhibitors and Lymphocytic Esophagitis : A Novel Association?

Salima Haque, Robert M. Genta, Miraca Life Sciences Research Institute, Irving, TX

Lymphocytic esophagitis was first described by Rubio et al. as an entity in 2006; however, in 2008 Purdy et al. reviewed 42 cases of lymphocytic esophagitis and dismissed it as a non-specific response of uncertain relevance. We recently reviewed the histopathology and clinical correlations of 42 patients with dense lymphocytic infiltrates in the esophageal mucosa and concluded that lymphocytic esophagitis is a specific type of inflammatory disorder of the esophagus.

To read the rest of this article, please contact Miraca Life Sciences

Choose Miraca for Your Patients

Learn more about Miraca's Anatomic Pathology services

Learn More »
TRADESHOWS >> FIND posters and presentations from past shows, and see where Miraca Life Sciences will be next.

Miraca has been extremely helpful to our office with Meaningful Use. It is such a complex task to undertake, and having knowledgeable people from Miraca to assist with each stage, work flow, and administration is invaluable. You guys have saved us countless hours. Everyone we’ve encountered from Miraca from the beginning like yourself [Rick Ludwico], and now with Joy [Rios], and Amy [Schmid] have been terrific. We count on you guys, and you have guided us throughout the whole process, making it so much easier than it would be otherwise!.
— Pam Kefer, Office Manager
Wallach Derma Center, Danville, Calif.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.
Get news from Miraca. Join our email list.